A phase 2 trial of Silence Therapeutics’ divesiran has hit its primary endpoint, emboldening the biotech to gear up for late-phase development of a potential challenger to Takeda and Protagonist Therapeutics’ rusfertide.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Resonate Group, an ambitious Nigerian indigenous company with global aspirations, that aligns her vision with strategic intent to provide innovative solutions and services in Oil & Gas, Maritime, Manufacturing, Finance, Steel, Healthcare, and Supply Chain sectors of the Nigerian economy...
Recent Post
Copyright 2024 - All Rights Reserved By Resonate Group | Designed By Nysut Digital Studios